• Home
  • Overbreadth in Biotech & Pharma: Supreme Court Perspectives

Overbreadth in Biotech & Pharma: Supreme Court Perspectives

  • 23 Nov 2023
  • 6:00 PM - 9:00 PM
  • GEORGE Restaurant, 111C Queen St E
  • 12

Registration


Registration is closed

In-person Dinner

GEORGE Restaurant (111C Queen St. E)

Thursday, November 23, 2023 at 6:00pm

Professor Siebrasse will provide a comparative perspective on the law of overbreadth in the context of biotech and pharmaceutical inventions, discussing the recent decision of the Supreme Court of the United States in Amgen Inc. v. Sanofi, 143 S. Ct. 1243 (2022) as well as the last word on overbreadth from the UK Supreme Court, Regeneron Pharmaceuticals, Inc. v Kymab Ltd. [2020] UKSC 27. Professor Siebrasse will also briefly discuss a proposal to implement a form of en banc review, inspired by US Federal Circuit practice, which would allow the Federal Court of Appeal to provide more effective guidance in contentious or developing areas of law.

Norman Siebrasse is a Professor of Law at the University of New Brunswick. His research focuses on patent law, particularly pharmaceutical patent law, patent remedies, and the intersection of intellectual property law and commercial law. His blog, Sufficient Description, comments on recent Canadian patent law cases. His writing, including his blog, is regularly judicially cited.

The presentation is eligible for up to one hour of substantive CPD. 

Please join us at 6PM for a cocktail reception followed by dinner and the presentation.

© 2013-2023 Toronto Intellectual Property Group
Powered by Wild Apricot Membership Software